Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 22, 2017

Sobi begins patient enrolment in A-SURE study haemophilia A treatment

Swedish Orphan Biovitrum (Sobi) has begun enrolling patients for the A-SURE study, which is designed to evaluate the effectiveness of Elocta compared to conventional FVIII products in the prophylactic treatment of patients with haemophilia A.

Swedish Orphan Biovitrum (Sobi) has begun enrolling patients for the A-SURE study, which is designed to evaluate the effectiveness of Elocta compared to conventional FVIII products in the prophylactic treatment of patients with haemophilia A.

Haemophilia is an agenetic disorder whereby the ability of a person's blood to clot is impaired.

The 24-month long A-SURE study expects to enrol 350 patients in around ten European countries.

Swedish Orphan Biovitrum medical and clinical sciences vice-president Stefan Lethagen said: “Elocta is the first extended half-life FVIII product approved by the European Commission and, as such, represents a meaningful step in the treatment of haemophilia.

"The 24-month long A-SURE study expects to enrol 350 patients in around ten European countries."

“Pharmacokinetic data from the phase lll trials indicate that Elocta can achieve higher FVIII levels in plasma over a longer period of time compared to the conventional haemophilia products given at the same dose.

“The clinical data shows that effective bleed prevention can be achieved with Elocta with extended dosing intervals. A-SURE is an important study that aims to evaluate the effectiveness of Elocta in a real world-setting.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The company has used Fc fusion technology to develop Elocta, a recombinant clotting factor VIII therapy developed for haemophilia A with prolonged circulation in the body.

In addition, Sobi has partnered with Biogen to develop and commercialise Elocta, also known as Eloctate.

However, Sobi has the final development and commercialisation rights of Elocta in Europe, North Africa, Russia and most Middle Eastern markets.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU